Novo Nordisk (NVO) Wins FDA Nod For Weight-Loss Injection

December 27, 2014 3:51 PM

5 0

Novo Nordisk said Wednesday the FDA has approved its experimental weight-loss treatment, Saxenda, to treat obesity in adults

Novo Nordisk A/S (ADR) (NYSE:NVO) announced Wednesday that the US Food and Drug Administration (FDA) has approved its experimental weight-loss injection, Saxenda, to treat obesity in adults.

Read more

To category page

Loading...